All In Biotech

Investigational drug · Phase 2

Acmopatide

Also called: CT-868, RO7795074

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Overweight, Obese, Type 1 Diabetes Mellitus.

Phase 2

Last checked: Nov 19, 2026Latest source record: Oct 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

0 still active

All registered trials

1

Any phase or sponsor naming "Acmopatide"

First trial start

2023

Nov 27, 2023

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "Acmopatide", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Overweight
  • Obese
  • Type 1 Diabetes Mellitus

Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic

Largest trials

Live from ClinicalTrials.gov: studies naming "Acmopatide" as an intervention, largest first.

All trials
  • Carmot Therapeutics, Inc.Industry

    NCT06062069 · 111 participants · Start Nov 27, 2023 · Primary completion Jul 7, 2025

    Drug: CT-868; CT-868 Pen Injector, Placebo · For: Overweight; Obese; Type 1 Diabetes Mellitus

    Sites: Concord, California; Escondido, California; Aurora, Colorado · 22 sites in all

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Overweight

  • CagrilintidePhase 320 trials

    Novo Nordisk · Obesity, Overweight, Type 2 Diabetes

  • BerobenatidePF-08653944, MET097Phase 319 trials

    Pfizer · Obesity, Overweight and/or Obesity, Overweight

  • RetatrutideLY3437943Phase 316 trials

    Eli Lilly · Obesity, Overweight, Type 2 Diabetes

  • Maridebart cafraglutideAMG 133Phase 314 trials

    Amgen · Obesity, Overweight, Obstructive Sleep Apnea

  • EloralintideLY3841136Phase 313 trials

    Eli Lilly · Obesity, Overweight, Diabetes Mellitus, Type 2

  • NNC0487-0111Phase 312 trials

    Novo Nordisk · Obesity, Overweight, Obstructive Sleep Apnoea

  • HRS-7535Phase 310 trials

    Shandong Suncadia Medicine Co., Ltd. · Type 2 Diabetes, Chronic Kidney Disease, Adults With Heart Failure, Mild Decrease in Ejection Fraction/Preserved Ejection Fraction, and Obesity

  • UBT251Phase 310 trials

    The United Bio-Technology (Hengqin) Co., Ltd. · Obesity, Obesity &Amp; Overweight, Diabetes Mellitus, Type 2

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.